MorphoSys AG (MOR)
17.89
+0.38
(+2.17%)
USD |
NASDAQ |
May 02, 16:00
17.89
0.00 (0.00%)
After-Hours: 20:00
MorphoSys Cash from Financing (TTM)
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| June 30, 2022 | 1.548B |
| March 31, 2022 | 1.567B |
| December 31, 2021 | 1.565B |
| September 30, 2021 | 1.914B |
| June 30, 2021 | 434.29M |
| March 31, 2021 | 1.049B |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | 0.3955M |
| September 30, 2019 | 3.540M |
| June 30, 2019 | -3.146M |
| March 31, 2019 | 210.94M |
| December 31, 2018 | 211.91M |
| September 30, 2018 | 211.24M |
| June 30, 2018 | 216.79M |
| March 31, 2018 | 9.257M |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | 122.19M |
| September 30, 2016 | -1.366M |
| June 30, 2016 | -1.254M |
| Date | Value |
|---|---|
| March 31, 2016 | -7.031M |
| December 31, 2015 | -4.512M |
| September 30, 2015 | -4.188M |
| June 30, 2015 | -3.659M |
| March 31, 2015 | 5.632M |
| December 31, 2014 | -5.212M |
| September 30, 2014 | -4.520M |
| June 30, 2014 | 169.16M |
| March 31, 2014 | 162.75M |
| December 31, 2013 | 173.48M |
| September 30, 2013 | 172.28M |
| June 30, 2013 | -1.152M |
| March 31, 2013 | 1.270M |
| December 31, 2012 | 2.065M |
| September 30, 2012 | 2.271M |
| June 30, 2012 | 1.641M |
| March 31, 2012 | 1.644M |
| December 31, 2011 | 1.845M |
| September 30, 2011 | 2.864M |
| June 30, 2011 | 4.276M |
| March 31, 2011 | 4.787M |
| December 31, 2010 | 3.866M |
| September 30, 2010 | 2.478M |
| June 30, 2010 | 2.065M |
| March 31, 2010 | 2.120M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-3.146M
Minimum
Jun 2019
1.914B
Maximum
Sep 2021
897.76M
Average
1.049B
Median
Mar 2021
Cash from Financing (TTM) Benchmarks
| Incyte Corp | -36.46M |
| Novartis AG | -10.24B |
| Immatics NV | 91.50M |
| Affimed NV | -6.734M |
| InflaRx NV | 57.36M |